This report provides an analysis of over 1,000 immunology partnering deals and agreements between leading healthcare companies. It details how and why companies enter into these partnerships, which mostly involve collaborative R&D and commercialization of discoveries at the development stage. Analyzing the contract terms and flexibility of prospective partners provides insight into negotiating processes and what can be expected during negotiations, including details on payment triggers. The initial chapters provide an orientation to immunology dealmaking activities.